You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 10,189,818

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,189,818

Title:	5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitfile (S)-lactate monohydrate
Abstract:	The disclosure herein includes 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitrile (S)-lactate monohydrate that inhibits Chk1/2 and is useful in the treatment of cancer.
Inventor(s):	Ennett-Shepard; Alessandra B. (Indianapolis, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	15/513,185
Patent Claims:	1. A compound which is 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitrile (S)-lactate monohydrate. 2. The compound according to claim 1 in crystalline form. 3. The compound according to claim 2, wherein the crystalline form is characterized by a X-ray powder diffraction pattern (CuKa radiation, .lamda.=1.54060 .ANG.) comprising a peak at 12.6, and one or more peaks at 24.8, 25.5, 8.1, 6.6, 12.3, and 16.3 (2.theta.+/-0.2.degree.). 4. A pharmaceutical composition comprising 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitrile (S)-lactate monohydrate and one or more pharmaceutically acceptable carriers, diluents, or excipients. 5. The pharmaceutical composition of claim 4, wherein 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitrile (S)-lactate monohydrate is in crystalline form. 6. The pharmaceutical composition of claim 5, wherein the crystalline form is characterized by a X-ray powder diffraction pattern (CuKa radiation, .lamda.=1.54060 .ANG.) comprising a first peak at 12.6, and one or more peaks at 24.8, 25.5, 8.1, 6.6, 12.3, and 16.3 (2.theta.+/-0.2.degree.). 7. A method of treating cancer comprising: administering to a patient in need thereof an effective amount of a compound which is 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitrile (S)-lactate monohydrate. 8. The method of claim 7, wherein the compound is in crystalline form. 9. The method of claim 8, where the crystalline form is characterized by a X-ray powder diffraction pattern (CuKa radiation, .lamda.=1.54060 .ANG.) comprising a peak at 12.6, and one or more peaks at 24.8, 25.5, 8.1, 6.6, 12.3, and 16.3 (2.theta.+/-0.2.degree.). 10. The method according to claim 7, wherein the compound is administered with one or more pharmaceutically acceptable carriers, diluents, or excipients. 11. The method according to claim 7, wherein the method further comprises administering ionizing radiation. 12. The method according to claim 7, wherein the method further comprises administering one or more chemotherapy agents. 13. The method according to claim 7, wherein the method further comprises administering a chemotherapy agent selected from the group consisting of 5-fluorouracil, hydroxyurea, gemcitabine, methotrexate, pemetrexed, doxorubicin, etoposide, cetuximab, cisplatin, taxol, and combinations thereof.

Details for Patent 10,189,818

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004	⤷ Try a Trial	2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007	⤷ Try a Trial	2039-02-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.